REFERENCES
1. Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol 2020;21:67-84.
2. Hastings MH, Maywood ES, Brancaccio M. Generation of circadian rhythms in the suprachiasmatic nucleus. Nat Rev Neurosci 2018;19:453-69.
3. Ralph MR, Foster RG, Davis FC, Menaker M. Transplanted suprachiasmatic nucleus determines circadian period. Science 1990;247:975-8.
4. Bloch KE, Brack T, Wirz-Justice A. Transient short free running circadian rhythm in a case of aneurysm near the suprachiasmatic nuclei. J Neurol Neurosurg Psychiatry 2005;76:1178-80.
5. Borgers AJ, Romeijn N, van Someren E, Fliers E, Alkemade A, Bisschop PH. Compression of the optic chiasm is associated with permanent shorter sleep duration in patients with pituitary insufficiency. Clin Endocrinol (Oxf) 2011;75:347-53.
6. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci 2012;35:445-62.
7. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014;71:589-95.
8. Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. JAMA Neurol 2018;75:582-90.
9. Masri S, Sassone-Corsi P. The emerging link between cancer, metabolism, and circadian rhythms. Nat Med 2018;24:1795-803.
10. Douma LG, Gumz ML. Circadian clock-mediated regulation of blood pressure. Free Radic Biol Med 2018;119:108-14.
11. Mason IC, Qian J, Adler GK, Scheer FAJL. Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. Diabetologia 2020;63:462-72.
14. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002;296:1991-5.
15. Zhang S, Wang R, Wang G. Impact of dopamine oxidation on dopaminergic neurodegeneration. ACS Chem Neurosci 2019;10:945-53.
16. Wang R, Sun H, Ren H, Wang G. α-Synuclein aggregation and transmission in Parkinson’s disease: a link to mitochondria and lysosome. Sci China Life Sci 2020;63:1850-9.
17. Kress GJ, Liao F, Dimitry J, et al. Regulation of amyloid-β dynamics and pathology by the circadian clock. J Exp Med 2018;215:1059-68.
18. Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 2019;363:880-4.
19. Sinforiani E, Terzaghi M, Pasotti C, Zucchella C, Zambrelli E, Manni R. Hallucinations and sleep-wake cycle in Alzheimer’s disease: a questionnaire-based study in 218 patients. Neurol Sci 2007;28:96-9.
20. Li S, Wang Y, Wang F, Hu LF, Liu CF. A new perspective for Parkinson’s disease: circadian rhythm. Neurosci Bull 2017;33:62-72.
21. He C, Hu Z, Jiang C. Sleep disturbance: an early sign of Alzheimer’s disease. Neurosci Bull 2020;36:449-51.
22. McCarter SJ, St Louis EK, Boeve BF. Sleep disturbances in frontotemporal dementia. Curr Neurol Neurosci Rep 2016;16:85.
23. Fifel K, De Boer T. The circadian system in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Handb Clin Neurol 2021;179:301-13.
24. Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in older persons. Sleep 2013;36:1027-32.
25. Hahn EA, Wang HX, Andel R, Fratiglioni L. A change in sleep pattern may predict Alzheimer disease. Am J Geriatr Psychiatry 2014;22:1262-71.
26. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011;306:613-9.
27. Jørgensen JT, Karlsen S, Stayner L, Hansen J, Andersen ZJ. Shift work and overall and cause-specific mortality in the Danish nurse cohort. Scand J Work Environ Health 2017;43:117-26.
28. Liguori C, Mercuri NB, Izzi F, et al. Obstructive sleep apnea is associated with early but possibly modifiable Alzheimer’s disease biomarkers changes. Sleep 2017; doi: 10.1093/sleep/zsx011.
29. Figueiro MG, Plitnick B, Roohan C, Sahin L, Kalsher M, Rea MS. Effects of a tailored lighting intervention on sleep quality, rest-activity, mood, and behavior in older adults with Alzheimer disease and related dementias: a randomized clinical trial. J Clin Sleep Med 2019;15:1757-67.
30. Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in Parkinson’s disease: clinical implications and management. Chin Med J (Engl) 2018;131:974-81.
31. Li T, Le W. Biomarkers for Parkinson’s disease: how good are they? Neurosci Bull 2020;36:183-94.
32. Zhang F, Niu L, Liu X, et al. Rapid eye movement sleep behavior disorder and neurodegenerative diseases: an update. Aging Dis 2020;11:315-26.
33. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442-6.
34. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time. J Neurol Neurosurg Psychiatry 2008;79:387-91.
35. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443-53.
36. Sani TP, Bond RL, Marshall CR, et al. Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer’s disease: a proof-of-principle behavioural study. eNeurologicalSci 2019;17:100212.
37. Bonakis A, Economou NT, Paparrigopoulos T, et al. Sleep in frontotemporal dementia is equally or possibly more disrupted, and at an earlier stage, when compared to sleep in Alzheimer’s disease. J Alzheimers Dis 2014;38:85-91.
38. Korhonen T, Katisko K, Cajanus A, et al. Comparison of prodromal symptoms of patients with behavioral variant frontotemporal dementia and Alzheimer disease. Dement Geriatr Cogn Disord 2020;49:98-106.
39. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56.
40. Renton AE, Majounie E, Waite A, et al. ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68.
41. Daoud H, Postuma RB, Bourassa CV, et al. C9orf72 repeat expansions in rapid eye movement sleep behaviour disorder. Can J Neurol Sci 2014;41:759-62.
42. Dedeene L, Van Schoor E, Vandenberghe R, Van Damme P, Poesen K, Thal DR. Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathol Commun 2019;7:189.
43. Palma JA, Fernandez-Cordon C, Coon EA, et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res 2015;25:69-75.
44. Lin JY, Zhang LY, Cao B, et al. Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity. Chin Med J (Engl) 2020;134:690-8.
45. Wu DD, Su W, Li SH, et al. A questionnaire-based study on clinical REM sleep behavior disorder and subtypes in multiple system atrophy. Eur Neurol 2021;84:368-74.
46. Wang H, Tang X, Zhou J, Xu Y. Excessive daytime sleepiness is associated with non-motor symptoms of multiple system atrophy: a cross-sectional study in China. Front Neurol 2021;12:798771.
47. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003;4:49-60.
48. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci 2018;21:1332-40.
49. Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting amyloidogenic processing of APP in Alzheimer’s disease. Front Mol Neurosci 2020;13:137.
50. Wang X. A bridge between the innate immunity system and amyloid-β production in Alzheimer’s disease. Neurosci Bull 2021;37:898-901.
51. De Jonghe C, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet 2001;10:1665-71.
53. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005-7.
54. Roh JH, Huang Y, Bero AW, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer’s disease pathology. Sci Transl Med 2012;4:150ra122.
55. Shokri-Kojori E, Wang GJ, Wiers CE, et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A 2018;115:4483-8.
56. Zhang F, Zhong R, Li S, et al. Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer’s disease preceding the disease pathology and cognitive decline. Alzheimers Dement 2019;15:590-7.
57. Qiu H, Zhong R, Liu H, Zhang F, Li S, Le W. Chronic sleep deprivation exacerbates learning-memory disability and Alzheimer’s disease-like pathologies in AβPP(swe)/PS1(ΔE9) mice. J Alzheimers Dis 2016;50:669-85.
58. Song H, Moon M, Choe HK, et al. Aβ-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer’s disease. Mol Neurodegener 2015;10:13.
59. Dufort-Gervais J, Mongrain V, Brouillette J. Bidirectional relationships between sleep and amyloid-beta in the hippocampus. Neurobiol Learn Mem 2019;160:108-17.
60. Bhuniya S, Goyal M, Chowdhury N, Mishra P. Intermittent hypoxia and sleep disruption in obstructive sleep apnea increase serum tau and amyloid-beta levels. J Sleep Res 2022; doi: 10.1111/jsr.13566.
61. Yun CH, Lee HY, Lee SK, et al. Amyloid burden in obstructive sleep apnea. J Alzheimers Dis 2017;59:21-9.
62. Huang H, Li M, Zhang M, et al. Sleep quality improvement enhances neuropsychological recovery and reduces blood Aβ42/40 ratio in patients with mild-moderate cognitive impairment. Medicina (Kaunas) 2021;57:1366.
63. He B, Nohara K, Park N, et al. The small molecule nobiletin targets the molecular oscillator to enhance circadian rhythms and protect against metabolic syndrome. Cell Metab 2016;23:610-21.
64. Kim E, Nohara K, Wirianto M, et al. Effects of the clock modulator nobiletin on circadian rhythms and pathophysiology in female mice of an Alzheimer’s disease model. Biomolecules 2021;11:1004.
65. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 2015;16:109-20.
66. Zhu Y, Zhan G, Fenik P, et al. Chronic sleep disruption advances the temporal progression of tauopathy in P301S mutant mice. J Neurosci 2018;38:10255-70.
67. Pablo-Fernandez E, Courtney R, Holton JL, Warner TT. Hypothalamic α-synuclein and its relation to weight loss and autonomic symptoms in Parkinson’s disease. Mov Disord 2017;32:296-8.
68. Pablo-Fernández E, Courtney R, Warner TT, Holton JL. A histologic study of the circadian system in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol 2018;75:1008-12.
69. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 2003;110:517-36.
70. Shprecher DR, Adler CH, Zhang N, et al. Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. Parkinsonism Relat Disord 2018;55:92-6.
71. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29:1010-8.
72. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016;79:940-9.
73. Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron 2019;103:627-41.e7.
74. Van Den Berge N, Ferreira N, Gram H, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 2019;138:535-50.
75. Iranzo A, Borrego S, Vilaseca I, et al. α-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. Sleep 2018; doi: 10.1093/sleep/zsy101.
76. Fernández-Arcos A, Vilaseca I, Aldecoa I, et al. Alpha-synuclein aggregates in the parotid gland of idiopathic REM sleep behavior disorder. Sleep Med 2018;52:14-7.
77. Forman MS, Trojanowski JQ, Lee VM. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol 2007;17:548-55.
78. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40:572-4.
79. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013;79:416-38.
80. Gabery S, Ahmed RM, Caga J, Kiernan MC, Halliday GM, Petersén Å. Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2021;47:979-89.
81. Calderón-Garcidueñas L, Rajkumar RP, Stommel EW, et al. Brainstem quadruple aberrant hyperphosphorylated tau, beta-amyloid, alpha-synuclein and TDP-43 pathology, stress and sleep behavior disorders. Int J Environ Res Public Health 2021;18:6689.
82. Cronin P, McCarthy MJ, Lim ASP, et al. Circadian alterations during early stages of Alzheimer’s disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimers Dement 2017;13:689-700.
83. Chen HF, Huang CQ, You C, Wang ZR, Si-qing H. Polymorphism of CLOCK gene rs 4580704 C > G is associated with susceptibility of Alzheimer’s disease in a Chinese population. Arch Med Res 2013;44:203-7.
84. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med 2015;47:e148.
85. Duncan MJ, Smith JT, Franklin KM, et al. Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer’s disease. Exp Neurol 2012;236:249-58.
86. Lee J, Kim DE, Griffin P, et al. Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer’s disease. Aging Cell 2020;19:e13078.
87. Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42.
88. Gunata M, Parlakpinar H, Acet HA. Melatonin: a review of its potential functions and effects on neurological diseases. Rev Neurol (Paris) 2020;176:148-65.
89. Cardinali DP. Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol (Lausanne) 2019;10:480.
90. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35:125-30.
91. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999;58:29-39.
92. Manni R, Cremascoli R, Perretti C, et al. Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. Sleep Med 2019;63:122-6.
93. Sulkava S, Muggalla P, Sulkava R, et al. Melatonin receptor type 1A gene linked to Alzheimer’s disease in old age. Sleep 2018;41:zsy103.
94. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009;47:82-96.
95. Pappolla MA, Matsubara E, Vidal R, et al. Melatonin treatment enhances Aβ lymphatic clearance in a transgenic mouse model of amyloidosis. Curr Alzheimer Res 2018;15:637-42.
96. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monit 2010;16:BR61-7.
97. Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014;71:463-9.
98. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005;6:459-66.
99. Bordet R, Devos D, Brique S, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol 2003;26:65-72.
100. Carriere CH, Kang NH, Niles LP. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson’s disease. Brain Res 2016;1633:115-25.
101. Li Y, Wang SM, Guo L, et al. Effects of melatonin levels on neurotoxicity of the medial prefrontal cortex in a rat model of Parkinson’s disease. Chin Med J (Engl) 2017;130:2726-31.
102. Rasheed MZ, Andrabi SS, Salman M, et al. Melatonin improves behavioral and biochemical outcomes in a rotenone-induced rat model of Parkinson’s disease. J Environ Pathol Toxicol Oncol 2018;37:139-50.
103. Acuña-Castroviejo D, Coto-Montes A, Monti M, Ortiz GG, Reiter RJ. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1996;60:PL23-9.
104. Jin BK, Shin DY, Jeong MY, et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 1998;245:61-4.
105. Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. J Pineal Res 2015;58:262-74.
106. Brito-Armas JM, Baekelandt V, Castro-Hernández JR, González-Hernández T, Rodríguez M, Castro R. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. Histol Histopathol 2013;28:999-1006.
107. Sae-Ung K, Uéda K, Govitrapong P, Phansuwan-Pujito P. Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J Pineal Res 2012;52:128-37.
108. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012;4:147ra111.
109. Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 2015;212:991-9.
110. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015;523:337-41.
111. Plog BA, Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol 2018;13:379-94.
112. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 2013;33:18190-9.
113. Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest 2017;127:3210-9.
114. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol 2018;17:1016-24.
115. Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science 2020;370:50-6.
116. Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain 2017;140:2691-705.
117. Ding XB, Wang XX, Xia DH, et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease. Nat Med 2021;27:411-8.
118. Hablitz LM, Plá V, Giannetto M, et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun 2020;11:4411.
119. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013;342:373-7.
120. Peng W, Achariyar TM, Li B, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease. Neurobiol Dis 2016;93:215-25.
121. Da Mesquita S, Louveau A, Vaccari A, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature 2018;560:185-91.
